SCS Capabilities — Public Source Meta-databases for Modeling
The development of a new drug is a high risk and costly activity that involves multiple decisions and tradeoffs. Model-based approaches for combining proprietary data on a specific compound with literature data of its likely competitors offer powerful tools for managing risks concerning dose selection, efficient and effective trial design, and "go/no-go" decisions.
The FDA has a growing base of experience with literature modeling and model-based drug development, as part of its Critical Path Initiative.
Pharsight compiles therapeutic data and information from public-source scientific literature to provide a ready context for model based meta-analysis that can accelerate quantitative assessment of your compound's performance relative to competing treatments. Meta-databases provide a publicly available start point for modeling efforts to address specific drug development program questions.
Pharsight currently offers public-source meta-databases in the following areas:
View Meta-database Summaries 
®
Therapeutic Domain |
Disease State/Indication-Level Meta-database |
| Anti-infectives | Fluoroquinolone Anti-infectives Hepatitis C Virus (HCV) |
| Anti- inflammatory |
Rheumatoid Arthritis (RA) |
Cardiovascular |
Congestive Heart Failure (CHF) |
Central Nervous System |
Depression |
Endocrine |
Type II Diabetes |
Gastro-intestinal |
Gastro-esophageal reflux disease (GERD) |
| Genito-urinary | Female Sexual Arousal Disorder (FSAD) |
| Pain |
Osteoarthritis Pain |
Respiratory |
Asthma
|
Pharsight scientists and expert staff are prepared to collaborate with you on your database development and model-building strategies. For more information about Pharsight meta-databases, please contact:
James Hayden
Senior Vice President, Global Sales
Email: jhayden@pharsight.com
Telephone: +1-650-314-3760
Nancy Risch
Vice President, Global Sales
Email: nrisch@pharsight.com
Telephone: +1-781-771-2243